Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Workiva Inc (WK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Workiva Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Workiva Inc trades at $52.99 (market cap $2.93B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 13.6× Workiva Inc's market cap. Which is the better fit depends on your goals.
| ALNY | WK | |
|---|---|---|
Market Cap | $39.89B | $2.93B |
Sector | Health | Technology |
52-Week High | $491.22 | $93.31 |
52-Week Low | $278.09 | $44.31 |
Enterprise Value | $38.15B | $2.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Workiva (WK) trades at $52.17, down slightly by 0.31% today, with a bullish technical outlook supported by moving averages and strong analyst sentiment. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $0.77 surpassing estimates. Revenue growth is solid, projected to reach $926 million in 2026, though profitability remains thin with a net margin of 1.53%. Recent news highlights investor conference participation and AI integration in financial reporting.
The stock presents growth potential with a consensus price target of $71.00, implying significant upside. However, high valuation multiples (P/E of 217.38) and reliance on sustained earnings expansion pose risks. Competitive pressures in regulatory software and macroeconomic sensitivity could challenge future performance. Institutional ownership trends and continued execution on guidance will be critical for maintaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
